CARA News and Press, Cara Therapeutics Inc. From 06/30/20

STAMFORD, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today an...

With so many companies struggling in the cannabis market , it's easy to predict doom and gloom for the whole industry, but that's far from the case. It's just an emerging market with a ridiculous upside, and some companies are bound to struggle. It may be inevitable that many in the sector won...

Based the recommendation from the independent Data Monitoring Committee, Cara Therapeutics (NASDAQ: CARA ) will increase the size of its Phase 2 dose-ranging clinical trial, KARE , evaluating oral Korsuva (CR845/difelikefalin) for the treatment of moderate-to-severe pruritis (itchy skin) ...

- Patient enrollment increased approximately 28% to maintain > 80% statistical power for primary endpoint and key registration endpoint of   > 4-point improvement responder analysis - - Full trial enrollment expected in fourth quarter of 2020 - STAMFORD, Conn., June...

STAMFORD, Conn., May 27, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, toda...

The following slide deck was published by Cara Therapeutics, Inc. in conjunction with their 2020 Q1 earnings Read more ...

Image source: The Motley Fool. Cara Therapeutics Inc   (NASDAQ: CARA) Q1 2020 Earnings Call May 11, 2020 , 4:30 p.m. ET Operator Continue reading

Cara Therapeutics, Inc. (CARA) Q1 2020 Earnings Conference Call May 11, 2020 4:30 PM ET Company Participants Jack Hildick-Smith - Stern Investor Relations Derek Chalmers - President & Chief Executive Officer Rick Makara - Vice President & Head of Accounting Conference ...

Cara Therapeutics (NASDAQ: CARA ): Q1 GAAP EPS of -$0.62 beats by $0.01 . Revenue of $8.1M (+84.1% Y/Y) beats by $3.39M . Press Release More news on: Cara Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,

STAMFORD, Conn., May 11, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today ann...